Wealthfront Advisers LLC Buys New Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Wealthfront Advisers LLC bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 109,566 shares of the biotechnology company’s stock, valued at approximately $2,060,000. Wealthfront Advisers LLC owned approximately 0.09% of Arrowhead Pharmaceuticals at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ARWR. R Squared Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at $38,000. Van ECK Associates Corp raised its stake in shares of Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares in the last quarter. KBC Group NV raised its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at $149,000. Finally, First Citizens Bank & Trust Co. acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at $205,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR opened at $15.36 on Friday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $14.23 and a twelve month high of $30.41. The firm has a market cap of $1.94 billion, a PE ratio of -2.97 and a beta of 0.92. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The business has a fifty day moving average of $19.09 and a 200-day moving average of $20.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the transaction, the director now owns 44,125 shares in the company, valued at $966,337.50. This trade represents a 7.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Richard Anzalone sold 133,333 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total value of $2,269,327.66. Following the completion of the transaction, the chief executive officer now owns 3,773,802 shares in the company, valued at approximately $64,230,110.04. This represents a 3.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 280,765 shares of company stock worth $5,227,313 over the last 90 days. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

ARWR has been the subject of a number of recent research reports. Sanford C. Bernstein cut their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Piper Sandler dropped their price objective on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.